Association of Vitamin D Binding Protein Variants with Chronic Mucus Hypersecretion in Iceland

American Journal of PharmacoGenomics

Volumn 4, Issue 1, 2004, Pages 63-68

  Laufs, Jürgen ^a   Andrason, Hjalti ^a   Sigvaldason, Andres ^b   Halapi, Eva ^a   Thorsteinsson, Leifur ^a   Jónasson, Kristján ^a   Söebech, Emilía ^a   Gislason, Thorarinn ^b   Gulcher, Jeffrey R ^a   Stefansson, Kari ^a   Hakonarson, Hakon ^a  

^a DECODE GENETICS   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D BINDING PROTEIN;

ARTICLE; BRONCHUS DISEASE; BRONCHUS MUCUS; CHRONIC MUCUS HYPERSECRETION; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; ICELAND; MAJOR CLINICAL STUDY; MUCUS SECRETION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ASTHMA; BASE SEQUENCE; CASE-CONTROL STUDIES; CHRONIC DISEASE; DNA PRIMERS; HUMANS; ICELAND; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAMIN D-BINDING PROTEIN;

BRONCHUS; MARTES PENNANTI;

EID: 12144290339     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404010-00007     Document Type: Article

References (17)

1. Daiger SP, Schanfield MS, Cavalli-Sforza LL. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci U S A 1975; 72: 2076-80
2. Schellenberg D, Paré PD, Weir TD, et al. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998; 157: 957-61
3. Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A 1991; 88: 8539-43
4. Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977; 63: 336-42
5. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990; 40: 173-6
6. Ishii T, Keicho N, Teramoto S, et al. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur Respir J 2001 Nov; 18 (5): 753-7
7. Kauffmann F, Kleisbauer JP, Cambon-De-Mouzon A, et al. Genetic markers in chronic air-flow limitation: a genetic epidemiologic study. Am Rev Respir Dis 1983; 127: 263
8. Sandford AJ, Chagani T, Weir TD, et al. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2001; 163: 469-73
9. Daiger SP, Miller M, Chakraborty R. Heritability of quantitative variation at the group-specific component (Gc) locus. Am J Hum Genet 1984; 36: 663-76
10. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Care Med 1995; 152 (5 Pt 2): S77-121
11. Gulcher JR, Kristjansson K, Gudbjartsson H, et al. Protection of privacy by third-party encryption in genetic research in Iceland. Eur J Hum Genet 2000; 8: 739-42
12. Barnes PJ. New treatments for chronic obstructive pulmonary disease. Curr Opin Pharmacol 2001; 1: 217-22
13. Barnes PJ. Future Advances in COPD Therapy. Respiration. 2001; 68: 441-8
14. National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma: Expert Panel Report 2, July 1997. Washington, DC: US Government Printing Office, 1997. NIH Publication No. 97-4051
15. American Thoracic Society. Standardization of spirometry, 1994. Update. Am J Respir Crit Care Med 1995; 152: 1107-36
16. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986; 72: 281-93
17. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEVI decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996; 153: 1530-5